Literature DB >> 7995314

Terminology in prescription-event monitoring.

K Kubota1, W H Inman.   

Abstract

The terminology used in prescription-event monitoring for postmarketing surveillance is described. It has been developed by the Drug Safety Research Unit while processing records of 500,000 events associated with the use of new chemical entities by 460,000 patients in England since 1981. Currently, the events are arranged in 24 classes which include 108 high-level terms and 1197 low-level terms. Low-level terms are used to code individual events reported by general practitioners, usually without an opinion about any possible causal relationship with a particular drug. Some low-level terms are lumped together as one high-level term when the event rates are estimated.

Entities:  

Mesh:

Year:  1994        PMID: 7995314     DOI: 10.1007/BF00196104

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  THE DESIGN AND LOGIC OF A MONITOR OF DRUG USE.

Authors:  D J FINNEY
Journal:  J Chronic Dis       Date:  1965-01

2.  Guidelines on postmarketing surveillance. Joint committee of ABPI, BMA, CSM, and RCGP.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1988-02-06

3.  Prescription-event monitoring: methodology and recent progress.

Authors:  N S Rawson; G L Pearce; W H Inman
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

  3 in total
  4 in total

1.  ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring.

Authors:  K Kubota; N Kubota; G L Pearce; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.

Authors:  D Layton; G L Pearce; S A Shakir
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: a pilot study of prescription-event monitoring in Japan.

Authors:  Kazuo Samizo; Eri Kawabe; Shiro Hinotsu; Tsugumichi Sato; Shigeru Kageyama; Chikuma Hamada; Yasuo Ohashi; Kiyoshi Kubota
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.